drugset / Trial / NCT02200757

Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer

NCT02200757

Phase 2 Completed 135 enrolled ImmunityBio, Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of aldoxorubicin compared to topotecan in subjects with metastatic small cell lung cancer.

Timeline

Start
2015-04-20
Primary completion
2017-05-15
Completion
2017-05-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Aldoxorubicin Small molecule 230 mg/m2 Intravenous
Comparator Topotecan Small molecule 1.5 mg/m2 Intravenous
Comparator Topotecan Small molecule 4 mg/m2 Intravenous